Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytics: prospects for new agents.

Daniel B McKenzie1, Robert G Wilcox

  • 1Department of Cardiovascular Medicine, Queen's Medical Centre, Derby Road, Nottingham NG7 2UH, UK. dan.mckenzie@nottingham.ac.uk

Expert Opinion on Pharmacotherapy
|January 9, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

β-Blockers, heart disease and COPD: current controversies and uncertainties.

Thorax·2016
Same author

Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged.

Heart (British Cardiac Society)·2015
Same author

Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study).

The American journal of cardiology·2014
Same author

Treatment of coronary aneurysms with covered stents: a review with illustrated case.

The Journal of invasive cardiology·2012
Same author

An unusual way of diagnosing acute inferior myocardial infarction.

BMJ case reports·2012
Same author

How should I treat severe calcific coronary artery disease?

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2011
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Thrombolytic therapy transformed acute myocardial infarction (AMI) care by restoring blood flow. This review covers current drugs, supportive treatments, and future innovations in AMI management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Thrombolytic therapy is a cornerstone in treating acute myocardial infarction (AMI).
  • Established thrombolytic agents have limitations, including incomplete patency and re-occlusion.
  • Novel agents have been developed to improve outcomes in AMI management.

Purpose of the Study:

  • To review currently available thrombolytic agents for AMI.
  • To discuss adjunctive therapies used with thrombolysis.
  • To examine future developments in thrombolytic therapy for AMI.

Main Methods:

  • Literature review of thrombolytic agents and therapies.
  • Analysis of current clinical practices and future research directions.

Main Results:

Related Experiment Videos

  • Current thrombolytic drugs have improved AMI outcomes but are not without flaws.
  • Adjunctive therapies play a crucial role in optimizing thrombolytic efficacy.
  • Emerging agents and strategies promise further advancements in AMI treatment.

Conclusions:

  • Thrombolytic therapy remains vital for AMI, with ongoing improvements.
  • Continued research into novel agents and combined therapies is essential.
  • Future developments may enhance the effectiveness and applicability of thrombolysis in AMI.